Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Tops Revenue Estimates

Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $1.34 per share versus the Zacks Consensus Estimate of a loss of$ 1.37. This compares to loss of $1.38 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 2.19%. A quarter ago, it was expected that this company would post a loss of$ 1.21 per share when it actually produced a loss of $1.31, delivering a surprise of -8.26%.Over the last four quarters, the company h ...